Lack of antihypertensive effect of interleukin-2 administration in humans

Barbara A Pockaj, S. A. Rosenberg

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A recent study reported that a single bolus dose of interleukin-2 (IL-2) decreased blood pressure to normal in adult hypertensive rats and prevented the development of spontaneous hypertension in young rats. The Surgery Branch of the National Cancer Institute has had extensive experience with the administration of IL-2. A review was performed focusing on the experience of IL-2 administration to cancer patients with established preexisting hypertension. Seventeen evaluable patients were identified. Sixteen of the patients experienced a return of their hypertension with the completion of therapy. One patient was able to stop his antihypertensive medications and remain normotensive for 3 months' follow-up. One normotensive patient developed hypertension after initiating IL-2 therapy. Our data do not demonstrate significant reduction in blood pressure in previously hypertensive patients undergoing high-dose IL-2 therapy.

Original languageEnglish (US)
Pages (from-to)456-459
Number of pages4
JournalJournal of Immunotherapy
Volume10
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Antihypertensive Agents
Interleukin-2
Hypertension
Blood Pressure
National Cancer Institute (U.S.)
Therapeutics
Neoplasms

Keywords

  • Antihypertensive effect
  • Humans
  • Interleukin-2

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Lack of antihypertensive effect of interleukin-2 administration in humans. / Pockaj, Barbara A; Rosenberg, S. A.

In: Journal of Immunotherapy, Vol. 10, No. 6, 1991, p. 456-459.

Research output: Contribution to journalArticle

@article{92b494f457354520b55f381b9537f17e,
title = "Lack of antihypertensive effect of interleukin-2 administration in humans",
abstract = "A recent study reported that a single bolus dose of interleukin-2 (IL-2) decreased blood pressure to normal in adult hypertensive rats and prevented the development of spontaneous hypertension in young rats. The Surgery Branch of the National Cancer Institute has had extensive experience with the administration of IL-2. A review was performed focusing on the experience of IL-2 administration to cancer patients with established preexisting hypertension. Seventeen evaluable patients were identified. Sixteen of the patients experienced a return of their hypertension with the completion of therapy. One patient was able to stop his antihypertensive medications and remain normotensive for 3 months' follow-up. One normotensive patient developed hypertension after initiating IL-2 therapy. Our data do not demonstrate significant reduction in blood pressure in previously hypertensive patients undergoing high-dose IL-2 therapy.",
keywords = "Antihypertensive effect, Humans, Interleukin-2",
author = "Pockaj, {Barbara A} and Rosenberg, {S. A.}",
year = "1991",
language = "English (US)",
volume = "10",
pages = "456--459",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Lack of antihypertensive effect of interleukin-2 administration in humans

AU - Pockaj, Barbara A

AU - Rosenberg, S. A.

PY - 1991

Y1 - 1991

N2 - A recent study reported that a single bolus dose of interleukin-2 (IL-2) decreased blood pressure to normal in adult hypertensive rats and prevented the development of spontaneous hypertension in young rats. The Surgery Branch of the National Cancer Institute has had extensive experience with the administration of IL-2. A review was performed focusing on the experience of IL-2 administration to cancer patients with established preexisting hypertension. Seventeen evaluable patients were identified. Sixteen of the patients experienced a return of their hypertension with the completion of therapy. One patient was able to stop his antihypertensive medications and remain normotensive for 3 months' follow-up. One normotensive patient developed hypertension after initiating IL-2 therapy. Our data do not demonstrate significant reduction in blood pressure in previously hypertensive patients undergoing high-dose IL-2 therapy.

AB - A recent study reported that a single bolus dose of interleukin-2 (IL-2) decreased blood pressure to normal in adult hypertensive rats and prevented the development of spontaneous hypertension in young rats. The Surgery Branch of the National Cancer Institute has had extensive experience with the administration of IL-2. A review was performed focusing on the experience of IL-2 administration to cancer patients with established preexisting hypertension. Seventeen evaluable patients were identified. Sixteen of the patients experienced a return of their hypertension with the completion of therapy. One patient was able to stop his antihypertensive medications and remain normotensive for 3 months' follow-up. One normotensive patient developed hypertension after initiating IL-2 therapy. Our data do not demonstrate significant reduction in blood pressure in previously hypertensive patients undergoing high-dose IL-2 therapy.

KW - Antihypertensive effect

KW - Humans

KW - Interleukin-2

UR - http://www.scopus.com/inward/record.url?scp=0025837472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025837472&partnerID=8YFLogxK

M3 - Article

C2 - 1768680

AN - SCOPUS:0025837472

VL - 10

SP - 456

EP - 459

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 6

ER -